10-Q: Theravance Biopharma Reports Second Quarter 2024 Results, YUPELRI Sales Stable, Ampreloxetine Development Progresses

Theravance Biopharma's second quarter 2024 results show stable YUPELRI sales and continued progress in the development of ampreloxetine.

Summary

• Theravance Biopharma reported a net loss of $16.5 million for the three months ended June 30, 2024, and a net loss of $28.2 million for the six months ended June 30, 2024.
• Revenue from the Viatris collaboration agreement was $14.3 million for the quarter and $28.8 million for the six months, representing a 4% and 19% increase respectively compared to the prior year periods.
• The company recognized a non-cash impairment charge of $3.0 million related to vacant laboratory spaces.
• YUPELRI net sales, of which Theravance Biopharma recognizes 35%, were $19.1 million for the quarter and $38.4 million for the six months.
• The company's cash, cash equivalents, and marketable securities totaled approximately $96.1 million as of June 30, 2024.
• The company expects its current cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months.
• The Phase 3 study for ampreloxetine is ongoing, with final patient enrollment expected in mid-2025 and top-line data approximately 6 months later.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is progress in ampreloxetine development and YUPELRI sales are stable, the company is still operating at a loss and faces significant risks. The non-cash impairment charge and the slight decrease in YUPELRI sales in the second quarter are also negative factors.

Positives

• Revenue from the Viatris collaboration agreement increased compared to the prior year periods.
• YUPELRI continues to be profitable on a brand basis.
• Viatris completed a registrational filing for YUPELRI in China, which could lead to future milestone payments and royalties.
• The company has sufficient cash to fund operations for at least the next twelve months.
• The ampreloxetine Phase 3 study is progressing as planned.

Negatives

• The company reported a net loss for both the three and six months ended June 30, 2024.
• YUPELRI net sales saw a slight decrease in the second quarter of 2024 compared to the prior year period.
• A non-cash impairment charge of $3.0 million was recognized due to vacant laboratory space.
• Interest income decreased due to lower cash balances.

Risks

• The company may never achieve or sustain profitability from its operations.
• YUPELRI's acceptance by physicians and patients may not continue to grow.
• Delays in clinical studies or adverse results could harm the business.
• The company faces substantial competition from companies with more resources.
• The company is subject to extensive regulation and may face penalties for non-compliance.
• The company may face competition from generic versions of YUPELRI.
• The company depends on third-party manufacturers and suppliers.
• The company may not be able to obtain additional financing on favorable terms.
• The company's reliance on third parties for clinical trials and manufacturing poses risks.
• The company's intellectual property may not be adequately protected.

Future Outlook

The company expects its current cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next twelve months. The company anticipates a more stable pricing environment for YUPELRI in 2025 and beyond and continued demand growth. The company expects to complete enrollment in the ampreloxetine Phase 3 study in mid-2025, with top-line data expected approximately 6 months later.

Management Comments

• The company's focus is to deliver medicines that make a difference in people's lives.
• The company is leveraging decades of expertise to develop and commercialize medicines.
• The company is focused on near-term value opportunities, including the ampreloxetine Phase 3 study.

Industry Context

The report highlights the competitive landscape for COPD treatments, noting the presence of short-acting nebulized bronchodilators and the recent launch of Verona Pharma's ensifentrine. It also mentions the potential approval of Sanofi and Regeneron's Dupixent for COPD. The company is positioning ampreloxetine as a potential first-in-class therapy for MSA patients with symptomatic nOH, a market with limited treatment options.

Comparison to Industry Standards

• The company's revenue is primarily driven by its collaboration with Viatris for YUPELRI, which is a common model for biopharmaceutical companies with approved products.
• The company's R&D expenses are typical for a company in the clinical development stage, with a focus on advancing ampreloxetine.
• The company's cash position is relatively strong, providing a runway for at least the next twelve months, which is a key metric for investors in the biotech sector.
• The company's reliance on third-party manufacturers and suppliers is a common practice in the pharmaceutical industry, but it also introduces risks related to supply chain disruptions.
• The company's ongoing patent litigation is a common occurrence in the pharmaceutical industry, particularly for products with significant market potential like YUPELRI. The settlements with some generic companies are a positive development, but the remaining litigation poses a risk.

Legal Proceedings

• The company is involved in patent infringement litigation against multiple generic companies seeking to market a generic version of YUPELRI.
• The company has settled litigation with some generic companies, granting them a license to market generic YUPELRI after April 23, 2039.
• The patent litigation against the three remaining generic companies, along with certain affiliates, and the subsequent ANDA filer, remains pending.

Stakeholder Impact

• Shareholders may be concerned about the company's continued net losses and the risks associated with its development programs.
• Employees may be affected by the company's strategic actions and cost-saving initiatives.
• Patients may benefit from the development of new treatments for COPD and nOH.
• Customers and suppliers may be affected by the company's business decisions and financial performance.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• Continue the Phase 3 clinical study for ampreloxetine (CYPRESS).
• Prepare for the potential NDA filing for ampreloxetine.
• Monitor the regulatory review of YUPELRI in China.
• Continue to manage the commercialization of YUPELRI in the US.
• Update the long-lived asset impairment assessment each quarterly period.

Key Dates

Keywords

Theravance Biopharma, YUPELRI, Ampreloxetine, Viatris, COPD, nOH, Clinical Trials, Revenue, Pharmaceutical, Biopharmaceutical